211 related articles for article (PubMed ID: 26054532)
1. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.
Veccia A; Caffo O; Fellin G; Mussari S; Ziglio F; Maines F; Tomio L; Galligioni E
Radiat Oncol; 2015 Jun; 10():130. PubMed ID: 26054532
[TBL] [Abstract][Full Text] [Related]
2. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.
Caffo O; Fellin G; Bolner A; Coccarelli F; Divan C; Frisinghelli M; Mussari S; Ziglio F; Malossini G; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):31-7. PubMed ID: 16765529
[TBL] [Abstract][Full Text] [Related]
5. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
7. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
8. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
10. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
11. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
12. Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution.
Rutten TP; Lawson JM; Marcu LG
Phys Med; 2013 Nov; 29(6):662-9. PubMed ID: 22975428
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
14. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer.
Emara AM; Chadwick E; Nobes JP; Abdelbaky AM; Laing RW; Langley SE
BJU Int; 2012 Apr; 109(7):994-1000. PubMed ID: 21854533
[TBL] [Abstract][Full Text] [Related]
15. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
17. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
19. [Quality of life after radiotherapy for prostate cancer].
Joly F; Degrendel AC; Guizard AV
Cancer Radiother; 2010 Oct; 14(6-7):519-25. PubMed ID: 20728393
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]